CELLECTIS SA Announces the Presentation of Results Demonstrating the Correction of an XP Mutation in a Patient’s Cell Line by Homologous Gene Targeting at the First French-German Meeting on DNA Repair, Damage Signaling and Carcinogenesis in Toulouse

Biocitech, France - September the 15th, 2007 - Cellectis SA, the rational genome engineering company specializing in the production of meganuclease recombination systems and in meganuclease engineering, today announced the presentation of results demonstrating the correction of a XP mutation in patient’s cell line by homologous gene targeting at the first French-German meeting on DNA repair, damage signaling and carcinogenesis in Toulouse.